SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
For the quarter ended June 30, 2002
Commission file number 0-11550
Pharmos Corporation
(Exact name of registrant as specified in its charter)
Nevada 36-3207413
(State or other jurisdiction of (IRS Employer Id. No.)
incorporation or organization)
99 Wood Avenue South, Suite 311
Iselin, NJ 08830
(Address of principal executive offices)
Registrant's telephone number, including area code: (732) 452-9556
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes |X| No |_|.
As of August 9, 2002 the Registrant had outstanding 56,580,241 shares of its
$.03 par value Common Stock.
Part I. Financial Information
Item 1 Financial Statements
Pharmos Corporation
(Unaudited)
Consolidated Balance Sheets
- --------------------------------------------------------------------------------
June 30, December 31,
2002 2001
------------- -------------
Assets
Cash and cash equivalents $ 26,855,683 $ 35,269,114
Other Receivables 1,481,401 690,067
Restricted cash 1,762,230 2,275,251
Prepaid expenses and other current assets 363,713 997,695
------------- -------------
Total current assets 30,463,027 39,232,127
Fixed assets, net 1,940,186 1,918,281
Restricted cash 60,272 3,090,550
Other assets 22,033 22,033
------------- -------------
Total assets $ 32,485,518 $ 44,262,991
------------- -------------
Liabilities and Shareholders' Equity
Accounts payable $ 448,680 $ 2,197,299
Accrued expenses 5,739,061 5,809,642
Accrued wages and other compensation 1,142,806 1,317,934
Convertible debentures, net 3,393,320 1,949,317
------------- -------------
Total current liabilities 10,723,867 11,274,192
Other liability 10,000 --
Convertible debentures, net -- 5,847,951
------------- -------------
Total liabilities 10,733,867 17,122,143
------------- -------------
Commitments and contingencies
Shareholders' equity
Common stock, $.03 par value; 80,000,000 shares authorized,
56,580,241 and 55,356,307 issued and outstanding
(excluding 14,189 and 18,356 shares in 2002 and 2001, held
in Treasury) in 2002 and 2001, respectively 1,697,406 1,660,688
Deferred compensation (149,053) (223,144)
Paid in capital 113,970,844 111,151,758
Accumulated deficit (93,767,546) (85,448,454)
------------- -------------
Total shareholders' equity 21,751,651 27,140,848
------------- -------------
Total liabilities and shareholders' equity $ 32,485,518 $ 44,262,991
------------- -------------
The accompanying notes are an integral part of these consolidated
financial statements.
2
Pharmos Corporation
(Unaudited)
Consolidated Statements of Operations
- --------------------------------------------------------------------------------
Three Months Ended June 30,
2002 2001
------------ ------------
Revenues
Product sales -- $ 1,480,737
Cost of Goods Sold -- 453,908
------------ ------------
Gross Margin -- 1,026,829
------------ ------------
Expenses
Research and development, net $ 2,183,508 1,914,812
Selling, general and administrative 938,205 1,110,604
Depreciation and amortization 171,812 164,066
------------ ------------
Total operating expenses 3,293,525 3,189,482
------------ ------------
Loss from operations (3,293,525) (2,162,653)
Other income (expense)
Interest income 144,799 226,208
Other expense, net (13,525) (4,315)
Interest expense (188,772) (425,985)
------------ ------------
Other expense, net (57,498) (204,092)
------------ ------------
Net loss ($3,351,023) ($2,366,745)
============ ============
Net loss per share
- basic and diluted ($.06) ($.04)
============ ============
Weighted average shares outstanding - basic and diluted 56,575,168 54,356,721
============ ============
The accompanying notes are an integral part of these consolidated
financial statements.
3
Pharmos Corporation
(Unaudited)
Consolidated Statements of Operations
- --------------------------------------------------------------------------------
Six Months Ended June 30,
2002 2001
------------ ------------
Revenues
Product sales -- $ 2,505,795
License fee -- 80,000
------------ ------------
Total Revenues -- 2,585,795
Cost of Goods Sold -- 865,249
------------ ------------
Gross Margin -- 1,720,546
------------ ------------
Expenses
Research and development, net $ 5,867,301 4,085,410
Selling, general and administrative 1,831,588 2,131,130
Depreciation and amortization 346,724 323,287
------------ ------------
Total operating expenses 8,045,613 6,539,827
------------ ------------
Loss from operations (8,045,613) (4,819,281)
Other income (expense)
Interest income 314,780 548,288
Other (expense) income, net (2,198) 6,142
Interest expense (586,061) (851,997)
------------ ------------
Other expense, net (273,479) (297,567)
------------ ------------
Net loss ($8,319,092) ($5,116,848)
============ ============
Net loss per share
- basic and diluted ($.15) ($.09)
============ ============
Weighted average shares outstanding - basic and diluted 56,509,919 54,265,381
============ ============
The accompanying notes are an integral part of these consolidated
financial statements.
4
Pharmos Corporation
(Unaudited)
Consolidated Statements of Cash Flows
- --------------------------------------------------------------------------------
Six Months Ended June 30,
2002 2001
------------ ------------
Cash flows from operating activities
Net loss ($8,319,092) ($5,116,848)
Adjustments to reconcile net loss to net
cash flow used in operating activities
Depreciation and amortization 346,724 323,287
Amortization of Debt Discount and Issuance costs 259,053 608,200
Amortization of FMV of change in Convertible Debt 213,794 --
Amortization of deferred compensation for options granted
below FMV 26,306 --
Non-cash compensation charge - consultant compensation 59,332 108,198
Changes in operating assets and liabilities
Inventory -- 188,909
Receivables (791,334) (464,419)
Prepaid expenses and other current assets 633,982 57,976
Advanced royalties -- 6,591
Accounts payable (1,748,619) (176,711)
Accrued expenses 47,011 404,065
Accrued wages and other compensation (175,128) 198,594
Other liability 10,000 --
------------ ------------
Net cash flows used in operating activities (9,437,971) (3,862,158)
Cash flows from investing activities
Purchases of fixed assets (368,629) (479,126)
------------ ------------
Net cash flows used in investing activities (368,629) (479,126)
------------ ------------
Cash flows from financing activities
Advances against future sales -- (399,327)
Proceeds from issuance of common stock
and exercise of warrants, net 12,870 236,363
Pricing adjustment for private placement, net -- (583,896)
Fees related to refinancing convertible debt (163,000)
Repayment of convertible debentures (2,000,000) --
Decrease (increase) in restricted cash 3,543,299 (50,099)
------------ ------------
Net cash provided (used in) by financing activities 1,393,169 (796,959)
Net decrease in cash and cash equivalents (8,413,431) (5,138,243)
Cash and cash equivalents at beginning of year 35,269,114 22,480,777
------------ ------------
Cash and cash equivalents at end of period $ 26,855,683 $ 17,342,534
============ ============
Supplemental information:
Interest paid $ 175,165 $ 1,938
Supplemental disclosure of non-cash financing activities:
Conversion of convertible debt and interest to equity $ 2,617,592 --
The accompanying notes are an integral part of these consolidated
financial statements.
5
Pharmos Corporation
Notes to Condensed Consolidated Financial Statements
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with generally accepted accounting
principles for interim financial information pursuant to the instructions
to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not
include all of the information and footnotes required by generally
accepted accounting principles for complete financial statements. In the
opinion of management, all adjustments, consisting of normal recurring
accrual adjustments, considered necessary for a fair presentation have
been included. Operating results for the three-month and six-month periods
ended June 30, 2002, are not necessarily indicative of the results that
may be expected for the year ended December 31, 2002.
1. The Company
Pharmos Corporation (the "Company") is a bio-pharmaceutical company that
discovers and develops new drugs to treat a range of inflammatory and
neurological disorders such as traumatic brain injury and stroke. Although
we do not currently have any approved products, we have an extensive
portfolio of drug candidates under development, as well as discovery,
preclinical and clinical capabilities. The Company has executive offices
in Iselin, New Jersey and conducts research and development through its
wholly owned subsidiary, Pharmos, Ltd., in Rehovot, Israel.
In October 2001, the Company sold its ophthalmic product line that
included Lotemax(R) and Alrex(R), two products that were being marketed,
and future extensions of loteprednol etabonate (see Note 5). As a result
of the sale, the Company is exclusively in the drug candidate development
stage.
2. Liquidity and Business Risks
The Company incurred operating losses since its inception through the year
ended December 31, 2000. During 2001, the Company recorded net income due
to the nonrecurring sale of its ophthalmic product line. At June 30, 2002,
the Company has an accumulated deficit of $93.8 million. Such losses have
resulted principally from costs incurred in research and development and
from general and administrative expenses. The Company has funded its
operations through the use of cash obtained principally from third party
financing. Management believes that the current cash and cash equivalents
of $26.9 million and restricted cash of $1.8 million as of June 30, 2002,
will be sufficient to support the Company's continuing operations through
early 2004.
The Company is continuing to actively pursue various funding options,
including additional equity offerings, strategic corporate alliances,
business combinations and the establishment of product related research
and development limited partnerships, to obtain additional financing to
continue the development of its products and bring them to commercial
markets.
3. Significant Accounting Policies
Revenue recognition
The Company earns license fees from the transfer of drug technology and
the related preclinical research data. License fee revenue is recognized
when all performance obligations are completed and the amounts are
considered collectible. Up-front license fees are deferred and recognized
when all performance obligations are completed. The Company had no product
sale revenues for the three and six month periods ending June 30, 2002 due
to the sale of its ophthalmic product line in October 2001 and does not
expect product sale revenues for the next few years.
6
Pharmos Corporation
Notes to Condensed Consolidated Financial Statements
Reclassifications
Certain amounts for 2001 have been reclassified to conform to the fiscal
2002 presentation. Such reclassifications did not have a material impact
on the Company's financial position or results of operations.
4. Net Loss Per Common Share
Basic and diluted net loss per common share was computed by dividing the
net loss attributable to common shareholders by the weighted average
number of shares of common stock. In accordance with the requirements of
Statement of Financial Accounting Standards No. 128, common stock
equivalents have been excluded from the calculation of diluted net loss
per common share as their inclusion would be antidilutive.
The following table summarized the equivalent number of common shares
assuming the related securities that were outstanding as of June 30, 2002
and 2001 had been converted.
2002 2001
--------- ---------
Stock options 3,289,030 2,530,768
Warrants 2,297,277 2,864,576
--------- ---------
Total potential dilutive securities assuming the
Company was in an income position 5,586,307 5,395,344
5. Collaborative Agreements
In June 1995, the Company entered into a marketing agreement (the
"Marketing Agreement") with Bausch & Lomb Pharmaceuticals, Inc. ("Bausch &
Lomb"), a shareholder of the Company, to market Lotemax(R) and Alrex(R),
on an exclusive basis in the United States following receipt of FDA
approval. The Marketing Agreement also covered the Company's other
loteprednol etabonate based product, LE-T. Under the Marketing Agreement,
Bausch & Lomb purchased the active drug substance (loteprednol etabonate)
from the Company. A second agreement, covering Europe, Canada and other
selected countries, was signed in December 1996 ("the New Territories
Agreement"). In October 2001, the Company sold its ophthalmic product
line, including the Company's rights under the above agreements to Bausch
& Lomb.
Through October 2001, Bausch & Lomb provided the Company with $5 million
in cash advances against future sales. Bausch & Lomb was entitled to
recoup the advances by withholding a certain percentage of payments to the
Company against payments for purchases of the active drug substance. With
the completion of the sale of the ophthalmic product line to Bausch & Lomb
in October 2001, all the advances have been repaid.
Sale of Ophthalmic Product line
In October 2001, Bausch & Lomb purchased all rights to the Company's
loteprednol etabonate (LE) ophthalmic product line for cash and assumption
of certain ongoing obligations. The Company received gross proceeds of
approximately $25 million in cash for its rights to Lotemax(R) and
Alrex(R), prescription products that were manufactured and marketed by
Bausch & Lomb under a 1995 Marketing Agreement with the Company. Bausch &
Lomb also acquired future extensions of LE formulations including LE-T, a
product candidate currently in Phase III clinical trial. Bausch & Lomb
will pay the Company additional fees depending on the approval date with
the FDA as follows: If the earlier of (a) commercial launch or (b) 6
months after FDA approval of LE-T (the "Triggering Event") occurs before
September 1, 2002 the Company will receive $14.7 million. This amount will
be reduced by $90,000 for each month thereafter to a minimum amount of
$13.3 million (if the Triggering Event occurs on December 31, 2003). If
the Triggering Event occurs after December 31, 2003, then the Company and
Bausch & Lomb will negotiate in good faith to agree upon the amount of
additional consideration that Bausch & Lomb will pay the Company but not
to exceed $13.3 million. The patent owner of LE-T is entitled to 11% of
the additional fees that the Company receives as a result of the
contingent payment, which will be net against any additional gain
recorded. The Triggering Event has not yet occurred.
7
Pharmos Corporation
Notes to Condensed Consolidated Financial Statements
Pharmos will receive an additional fee of up to $10 million if the
following occurs: (a) net sales of LE-T in the first 12 months after
commercial launch are at least $7.5 million and (b) net sales of LE-T in
the second twelve consecutive months after commercial launch (i) exceed
$15.0 million and (ii) are greater than net sales in (a) above. Future
payments will be included in the Company's income when all contingencies
are resolved. The patent owner is also entitled to 14.3% of the additional
fees that the Company receives as a result of these contingent payments.
The Company's only future obligation to Bausch & Lomb after the sale is to
pay up to $3.75 million in research and development cost relating to LE-T,
of which $600,000 was withheld from the sales proceeds. The entire $3.75
million was netted against the gain on sale recorded. The Company has a
passive role as a member of a joint committee overseeing the development
of LE-T. As of June 30, 2002, the Company's share of these research and
development-related LE-T expenses to date was estimated at approximately
$600,000.
As a result of this transaction, the Company recorded a gain of $16.3
million in the fourth quarter of 2001. The Company incurred transaction
and royalty costs of approximately $2 million. The Company also
compensated the LE patent owner approximately $2.7 million ($1.5 million
paid upon closing and $1.2 million of this amount is to be paid in October
2002) from the proceeds of the sale of Lotemax and Alrex in return for his
consent to the Company's assignment of its rights under the license
agreement to Bausch & Lomb.
6. Common Stock Transactions
During the first quarter of 2002, the Company issued 1,217,485 shares of
its common stock upon the conversion of $2.6 million of the Company's
convertible debentures relating to the September 2000 offering. The
conversion amount includes $100,000 of accrued interest. Additionally, $2
million of convertible debentures were repaid in January 2002, leaving
$3.5 million of outstanding principal due in June 2003. In connection with
the conversion and repayment, $3.6 million of restricted cash was released
to the Company.
During the first half of 2001, the Company modified the terms of certain
incentive and nonqualified stock options granted to three of the Company's
former employees who entered into consulting relationships with the
Company. Accordingly, the Company expensed $108,198 as consultant
compensation for the value of the currently vested options and recorded
$273,495 as deferred compensation for the value of the unvested options.
During the second quarter of 2001, the Company issued 38,750 shares of its
common stock upon the exercise of warrants, and received consideration of
$50,863.
During the first quarter of 2001, the Company paid $572,539 and issued
182,964 shares (valued at $400,325 at the date of issue) of the common
stock of the Company to the investors in the September 2000 private
placement of convertible debentures and common stock. The payment of cash
and stock were the options chosen by the Company and represent adjustments
to the pricing based upon the Company's stock price during the adjustment
period. Under the terms of the agreements, no further adjustments are due.
During the first quarter of 2001, the Company issued 106,000 shares of its
common stock upon the exercise of warrants, and received consideration of
$185,500.
On July 19, 2002, an amendment was filed to the Company's Restated
Articles of Incorporation which increased the number of authorized shares
of common stock from 80 million to 110 million shares.
8
Pharmos Corporation
Notes to Condensed Consolidated Financial Statements
7. Segment and Geographic Information
The Company is active in one business segment: designing, developing,
selling and marketing pharmaceutical products. The Company maintains
development operations in the United States and Israel. The Company's
selling operations are maintained in the United States.
Geographic information for the three and six months ending June 30, 2002
and 2001 are as follows:
Three months ended June 30, Six months ended June 30,
--------------------------- -------------------------
2002 2001 2002 2001
---- ---- ---- ----
Net revenues
United States $ -- $ 1,480,737 $ -- $ 2,585,795
Israel -- -- -- --
----------- ----------- ----------- -----------
$ -- $ 1,480,737 $ -- $ 2,585,795
=========== =========== =========== ===========
Net loss
United States ($3,188,944) ($2,225,782) ($8,016,991) ($4,854,713)
Israel (162,079) (140,963) (302,101) (262,135)
----------- ----------- ----------- -----------
($3,351,023) ($2,366,745) ($8,319,092) ($5,116,848)
=========== =========== =========== ===========
9
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
This discussion and analysis of our financial condition and results of
operations contains forward-looking statements that involve risks and
uncertainties. We have based these forward-looking statements on our current
expectations and projections of future events. Such statements reflect our
current views with respect to future events and are subject to unknown risks,
uncertainty and other factors that may cause results to differ materially from
those contemplated in such forward looking statements. In addition, the
following discussion should be read in conjunction with the consolidated
financial statements and the related notes thereto included elsewhere in this
report.
Through the end of the third quarter of 2001, the Company generated revenues
from product sales, however, the Company continues to be dependent upon external
financing, interest income, and research and development contracts to pursue its
intended business activities. The Company had not been profitable from inception
through 2000 and has incurred a cumulative net loss of $93.8 million through
June 30, 2002. Net income in 2001 resulted from non-recurring income from the
sale of the ophthalmic product line. Losses have resulted principally from costs
incurred in research activities aimed at identifying and developing the
Company's product candidates, clinical research studies, the write-off of
purchased research and development, and general and administrative expenses. The
Company expects to incur additional losses over the next several years as the
Company's research and development and clinical trial programs continue. The
Company's ability to achieve profitability is dependent on its ability to
develop and obtain regulatory approvals for its product candidates, to enter
into agreements for product development and commercialization with strategic
corporate partners and contract to develop or acquire the capacity to
manufacture and sell its products. See "Management's Discussion and Analysis of
Financial Condition and Results of Operations -- Liquidity and Capital
Resources."
Results of Operations
Quarters ended June 30, 2002 and 2001
There were no product sales or cost of goods sold for the three months ended
June 30, 2002. Product sales revenue totaled $1,480,737 and cost of goods sold
totaled $453,908 for the quarter ended June 30, 2001. The decrease in both
product sales and cost of goods sold is due to the sale of the Company's
ophthalmic product line to Bausch & Lomb in October 2001. Bausch & Lomb was the
Company's marketing partner for its ophthalmic product line.
Total operating expenses increased $104,043 or 3%, from $3,189,482 in 2001 to
$3,293,525 in 2002. The increase is primarily due to increased research and
development costs. General and administrative expenses decreased while
depreciation expense increased by a small amount.
10
The company considers major research & development projects to be those projects
that have reached at least Phase II level of clinical development. The only
major project of the Company is the development of dexanabinol for the treatment
of traumatic brain injury, which is currently involved in Phase III testing in
Europe and Israel. During the second quarter of 2002, the cost of the project
was $1.9 million. Total costs since the project entered Phase II development in
1996 through June 30, 2002 are $18.8 million. Enrollment in the current Phase
III trial is expected to continue until the end of 2003. The principal costs of
completing the project include patient enrollment, production of the drug
product, collection and evaluation of the data, and management of the project.
The primary uncertainties in the completion of the project are the time required
to enroll sufficient numbers of patients in the study, the results of the study
upon its conclusion, and the Company's ability to produce sufficient quantities
of drug product under current Good Manufacturing Practice conditions. Should the
uncertainties delay completion of the project on the current timetable, the
Company may experience additional costs that cannot be accurately estimated. If
the Phase III trial of dexanabinol for the treatment of traumatic brain injury
is successfully completed, the Company can expect to begin to earn revenues upon
marketing approval as early as 2005; however, should our product candidate
experience set backs or should a product fail to achieve FDA approval and market
acceptance for any reason, it would have a material adverse affect on our
business.
Expenses for other research & development projects in earlier stages of
development for the second quarters of 2002 and 2001 were $791,575 and
$1,024,122, respectively. Total research and development expenses for the second
quarters of 2002 and 2001 were $2,183,375 and $1,858,843, respectively. The
company received from the Office of the Chief Scientist of Israel's Ministry of
Industry and Trade grant money of $878,616 and $234,329 during the second
quarters of 2002 and 2001, respectively, which reduced the research and
development expenses.
Selling, general and administrative expenses decreased by $172,399 or 16%, from
$1,110,604 in 2001 to $938,205 in 2002. The decrease relates to a reduction in
the overhead allocation and reduction in headcount.
Other expense, net, decreased by $146,594 or 72%, from $204,092 in 2001 to
$57,498 in 2002. The decrease was attributable to the lower debt payable at June
30, 2002 resulting from (i) the conversion from debt to equity in the first
quarter of 2002 of $2.6 million of our Convertible Debentures issued in 2000,
and (ii) the repayment of $2 million of the Convertible Debentures in the first
quarter of 2002. This conversion and repayment resulted in lower interest
expense.
Six Months ended June 30, 2002 and 2001
There were no product sales or cost of goods sold for the six months ended June
30, 2002. Product sales revenue totaled $2,505,795 and cost of goods sold
totaled $865,249 for the six months ended June 30, 2001. The decrease in both
product sales and cost of goods sold is due to the sale of the Company's
ophthalmic product line to Bausch & Lomb in October 2001. Bausch & Lomb was the
Company's marketing partner for its ophthalmic product line.
Total operating expenses increased $1,505,786 or 23%, from $6,539,827 in 2001 to
$8,045,613 in 2002. The increase is principally due to higher research and
development expenses, and, to a lesser extent, increased depreciation, which was
partially offset by a decrease in general and administrative expenses.
11
The company considers major research & development projects to be those projects
that have reached at least Phase II level of clinical development. The only
major project of the Company is the development of dexanabinol for the treatment
of traumatic brain injury, which is currently involved in Phase III testing in
Europe and Israel. During the first six months of 2002, the cost of the project
was $4.1 million. Total costs since the project entered Phase II development in
1996 through June 30, 2002 are $18.8 million. Enrollment in the current Phase
III trial is expected to continue until the end of 2003. The principal costs of
completing the project include patient enrollment, production of the drug
product, collection and evaluation of the data, and management of the project.
The primary uncertainties in the completion of the project are the time required
to enroll sufficient numbers of patients in the study, the results of the study
upon its conclusion, and the Company's ability to produce sufficient quantities
of drug product under current Good Manufacturing Practice conditions. Should the
uncertainties delay completion of the project on the current timetable, the
Company may experience additional costs that cannot be accurately estimated. If
the Phase III trial of dexanabinol for the treatment of traumatic brain injury
is successfully completed, the Company can expect to begin to earn revenues upon
marketing approval as early as 2005; however, should our product candidate
experience set backs or should a product fail to achieve FDA approval and market
acceptance for any reason, it would have a material adverse affect on our
business.
Expenses for other research & development projects in earlier stages of
development for the first six months of 2002 and 2001 were $2,117,057 and
$1,771,646, respectively. Total research and development expenses for the first
six months of 2002 and 2001 were $5,867,302 and $3,958,474, respectively. The
company received from the Office of the Chief Scientist of Israel's Ministry of
Industry and Trade grant money of $1,188,842 and $438,696 during the first six
months of 2002 and 2001, respectively which reduced the research and development
expenses.
Selling, general and administrative expenses decreased by $299,542 or 14%, from
$2,131,130 in 2001 to $1,831,588 in 2002. The decrease relates to a reduction in
the overhead allocation.
Depreciation and amortization expenses increased by $23,437, or 7%, from
$323,287 in 2001 to $346,724 in 2002, reflecting increased depreciation expense
relating to laboratory equipment purchases.
Other expense, net, decreased by $24,088 or 8%, from $297,567 in 2001 to
$273,479 in 2002.The decrease was attributable to the lower debt payable at June
30, 2002 resulting from (i) the conversion from debt to equity in the first
quarter of 2002 of $2.6 million of our Convertible Debentures issued in 2000,
and (ii) the repayment of $2 million of the Convertible Debentures in the first
quarter of 2002. This conversion and repayment resulted in lower interest
expense.
Liquidity and Capital Resources
While the Company received revenues from 1998 until the third quarter of 2001
from the sale of its approved products, it has incurred cumulative operating
losses since its inception and had an accumulated deficit of $93.8 million at
June 30, 2002. The Company has financed its operations with public and private
offerings of securities, advances and other funding pursuant to a marketing
agreement with Bausch & Lomb, research contracts, license fees, sales and
interest income.
The Company had working capital of $18.0 million as of June 30, 2002 (excluding
restricted cash of $1.8 million). Included in the current assets of $30.5
million is $26.9 million related to cash and cash equivalents.
12
In October 2001, Bausch & Lomb purchased all rights to the Company's loteprednol
etabonate (LE) ophthalmic product line for cash and assumption of certain
ongoing obligations. The Company received gross proceeds of approximately $25
million in cash for its rights to Lotemax(R) and Alrex(R), prescription products
that are made and marketed by Bausch & Lomb under a 1995 Marketing Agreement
with the Company; in addition, Bausch & Lomb also acquired future extensions of
LE formulations including LE-T, a product currently in Phase III clinical trial.
The Company has had no product sales beginning in the fourth quarter of 2001.
Bausch & Lomb will pay the Company up to an additional maximum gross proceeds of
$14.7 million, with the actual payment price based on the date of the earlier of
commercial launch or the six month anniversary of FDA approval of this new
combination therapy. An additional milestone payment of up to $10 million could
be paid to the Company to the extent sales of the new product exceed an
agreed-upon forecast in the first two years. The Company has a passive role as a
member of a joint committee overseeing the development of LE-T and has an
obligation to Bausch & Lomb to fund up to a maximum of $3.75 million of the LE-T
development cost. As a result of this transaction, the Company recorded a net
gain of $16.3 million during the fourth quarter of 2001. The company recorded an
accrual of $3.75 million representing the Company's maximum obligation in the
continuing clinical development of LE-T. The Company incurred transaction and
royalty costs of approximately $2 million. The Company also compensated the LE
patent owner approximately $2.7 million ($1.5 million paid upon closing and $1.2
million of this amount is to be paid in October 2002 and is included in
restricted cash) from the proceeds of the sale of Lotemax and Alrex in return
for his consent to the Company's assignment of its rights under the license
agreement to Bausch & Lomb. Additionally, the patent owner will receive 11% of
the proceeds payable to the Company following FDA approval of LE-T, as well as
14.3% of its milestone payment, if any.
As of June 30, 2002, we had the following commitments and long-term obligations:
Last six
months of
2002 2003 2004 2005 Thereafter Total
---- ---- ---- ---- ---------- -----
Operating Leases $ 181,848 $ 253,352 $227,496 $61,986 $72,015 $ 796,697
Convertible debentures,
excluding interest 3,500,000 3,500,000
R&D commitments 380,874 190,437 571,311
---------- ---------- -------- ------- ------- ----------
Grand total $ 562,722 $3,943,789 $227,496 $61,986 $72,015 $4,868,008
In its agreement with a clinical research organization that is assisting in the
European Phase III trials for dexanabinol for traumatic brain injury, the
Company is obligated to make certain periodic progress payments which are based
on the number of patients successfully enrolled in the trials. Subsequent to
June 30, 2002, patient enrollment in the dexanabinol's Phase III traumatic brain
injury clinical trial reached a milestone generating an obligation that was paid
in the third Quarter of approximately $400,000.
Management believes that cash and cash equivalents of $26.9 million and the
total restricted cash balance of $1.8 million as of June 30, 2002, will be
sufficient to support the Company's continuing operations through early 2004.
The Company is continuing to actively pursue various funding options, including
additional equity offerings, strategic corporate alliances, business
combinations and the establishment of product related research and development
limited partnerships, to obtain additional financing to continue the development
of its products and bring them to commercial markets.
We have assessed our vulnerability to certain market risks, including interest
rate risk associated with financial instruments included in cash and cash
equivalents and our convertible debentures. Due to the relatively short-term
nature of these investments we have determined that the risks associated with
interest rate fluctuations related to these financial instruments do not pose a
material risk to us.
13
Statements made in this document related to the development, commercialization
and market expectations of the Company's drug candidates, to the establishment
of corporate collaborations, and to the Company's operational projections are
forward-looking and are made pursuant to the safe harbor provisions of the
Securities Litigation Reform Act of 1995. Such statements involve risks and
uncertainties which may cause results to differ materially from those set forth
in these statements. Among the factors that could result in a materially
different outcome are the inherent uncertainties accompanying new product
development, action of regulatory authorities and the results of further trials.
Additional economic, competitive, governmental, technological, marketing and
other factors identified in Pharmos' filings with the Securities and Exchange
Commission could affect such results.
14
Part II
Other Information
Item 1 Legal Proceedings NONE
Item 2 Changes in Securities NONE
Item 3 Defaults upon Senior Securities NONE
Item 4 Submissions of Matters to Vote of Security Holders NONE
Item 5 Other Information NONE
Item 6 Exhibits and Reports on Form 8-K
Number Exhibit
------ -------
3 Certificate of Amendment of Restated Articles of
Incorporation dated July 12, 2002
99.1 Certification by Chief Executive Officer
99.2 Certification by Chief Financial Officer
15
SIGNATURE PAGE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
PHARMOS CORPORATION
Dated: August 12, 2002
by: /s/ Robert W. Cook
---------------------------
Robert W. Cook
Executive Vice President and
Chief Financial Officer
(Principal Accounting and
Financial Officer)
16